Figure 1.
Risk of incident VTE according to initial OAC therapy with dabigatran, rivaroxaban or apixaban versus warfarin* in patients with non-valvular AF, by patient characteristics, MarketScan databases, 2010 to September 30, 2015.
*Matched on HDPS 1:1
AF: atrial fibrillation; OAC, oral anticoagulant; VTE: venous thromboembolism.